Prognostic Impact of CYP2C19 Genotypes on Long-Term Clinical Outcomes in Older Patients After Percutaneous Coronary Intervention
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Ju Hyeon | - |
dc.contributor.author | Lee, Seung-Jun | - |
dc.contributor.author | Cha, Jung-Joon | - |
dc.contributor.author | Park, Jae Hyoung | - |
dc.contributor.author | Hong, Soon Jun | - |
dc.contributor.author | Ahn, Tae Hoon | - |
dc.contributor.author | Kim, Byeong-Keuk | - |
dc.contributor.author | Chang, Kiyuk | - |
dc.contributor.author | Park, Yongwhi | - |
dc.contributor.author | Song, Young Bin | - |
dc.contributor.author | Ahn, Sung Gyun | - |
dc.contributor.author | Suh, Jung-Won | - |
dc.contributor.author | Lee, Sang Yeub | - |
dc.contributor.author | Cho, Jung Rae | - |
dc.contributor.author | Her, Ae-Young | - |
dc.contributor.author | Jeong, Young-Hoon | - |
dc.contributor.author | Kim, Hyo-Soo | - |
dc.contributor.author | Kim, Moo Hyun | - |
dc.contributor.author | Shin, Eun-Seok | - |
dc.contributor.author | Lim, Do-Sun | - |
dc.date.accessioned | 2024-06-04T00:30:20Z | - |
dc.date.available | 2024-06-04T00:30:20Z | - |
dc.date.issued | 2024-05 | - |
dc.identifier.issn | 2047-9980 | - |
dc.identifier.issn | 2047-9980 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/74009 | - |
dc.description.abstract | BACKGROUND: Carriers of CYP2C19 loss-of-function alleles have increased adverse events after percutaneous coronary intervention, but limited data are available for older patients. We aimed to evaluate the prognostic impact of CYP2C19 genotypes on clinical outcomes in older patients after percutaneous coronary intervention. RESULTS: The study included 1201 older patients (aged ≥75 years) who underwent percutaneous coronary intervention and received clopidogrel-based dual antiplatelet therapy in South Korea. Patients were grouped on the basis of CYP2C19 genotypes. The primary outcome was 3-year major adverse cardiac events, defined as a composite of cardiac death, myocardial infarction, and stent thrombosis. Older patients were grouped into 3 groups: normal metabolizer (36.6%), intermediate metabolizer (48.1%), and poor metabolizer (15.2%). The occurrence of the primary outcome was significantly different among the groups (3.1, 7.0, and 6.2% in the normal metabolizer, intermediate metabolizer, and poor metabolizer groups, respectively; P=0.02). The incidence rate of all-cause death at 3 years was greater in the intermediate metabolizer and poor metabolizer groups (8.1% and 9.2%, respectively) compared with that in the normal metabolizer group (3.5%, P=0.03) without significant differences in major bleeding. In the multivariable analysis, the intermediate metabolizer and poor metabolizer groups were independent predictors of 3-year clinical outcomes. CONCLUSIONS: In older patients, the presence of any CYP2C19 loss-of-function allele was found to be predictive of a higher incidence of major adverse cardiac events within 3 years following percutaneous coronary intervention. This finding suggests a need for further investigation into an optimal antiplatelet strategy for older patients. BACKGROUND: URL: https://clinicaltrials.gov. Identifier: NCT04734028. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | WILEY | - |
dc.title | Prognostic Impact of CYP2C19 Genotypes on Long-Term Clinical Outcomes in Older Patients After Percutaneous Coronary Intervention | - |
dc.type | Article | - |
dc.identifier.doi | 10.1161/JAHA.123.032248 | - |
dc.identifier.bibliographicCitation | Journal of the American Heart Association, v.13, no.10 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 001228221200012 | - |
dc.identifier.scopusid | 2-s2.0-85194013134 | - |
dc.citation.number | 10 | - |
dc.citation.title | Journal of the American Heart Association | - |
dc.citation.volume | 13 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | aged | - |
dc.subject.keywordAuthor | cytochrome P‐450 2C19 | - |
dc.subject.keywordAuthor | genetics | - |
dc.subject.keywordAuthor | genotype | - |
dc.subject.keywordAuthor | percutaneous coronary intervention | - |
dc.subject.keywordAuthor | polymorphism | - |
dc.subject.keywordPlus | DUAL ANTIPLATELET THERAPY | - |
dc.subject.keywordPlus | PLATELET REACTIVITY | - |
dc.subject.keywordPlus | POPULAR AGE | - |
dc.subject.keywordPlus | CLOPIDOGREL | - |
dc.subject.keywordPlus | TICAGRELOR | - |
dc.subject.keywordPlus | EVENTS | - |
dc.subject.keywordPlus | POLYMORPHISMS | - |
dc.subject.keywordPlus | VALIDATION | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | PRASUGREL | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.